Skip to content

Study · Not a test of the peptide alone · 2004

9 results

PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.

Thakur ML, Aruva MR, Gariepy J, Acton P, Rattan S, Prasad S, Wickstrom E, Alavi A

Journal of nuclear medicine : official publication, Society of Nuclear Medicine1 Aug 2004Cited by 47 (Europe PMC)

PMID15299065 (opens in a new tab)PMCIDPMC6540993 (opens in a new tab)PepBankPUB-15299065
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Pharmacokinetics

    In vivo, more than 98% of (64)Cu circulating in plasma remained as (64)Cu-TP3982.

    In plain wordsIn animals, the labelled VIP analog stayed intact in the blood.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableIn vivo plasma stability of (64)Cu-TP3982
    Study

    n: not reported in source

    Outcome group
    Diagnostic imaging · Cancer

    Measurements

    Intact radiolabelled analog in plasma
    > 98%
    in vivo

    Source sentences

    Summary
    In vivo, >98% of (64)Cu circulating in plasma remained as (64)Cu-TP3982.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Pharmacokinetics

    Of the (64)Cu excreted in urine, over 98% at 4 h, 89.9% at 20 h and 85% at 24 h was bound to TP3982.

    In plain wordsIn animals, most of the label in urine was still attached to the VIP analog.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicable(64)Cu bound to TP3982 in urine
    Study

    n: not reported in source

    Outcome group
    Diagnostic imaging · Cancer

    Source sentences

    Summary
    Of the (64)Cu excreted in urine 4, 20, and 24 h after injection, >98%, 89.9% +/- 0.9%, and 85% +/- 3%, respectively, were bound to TP3982.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Pharmacokinetics

    In mice with T47D breast tumor xenografts, 4-h tumor uptake was higher for (64)Cu-TP3982 than for (99m)Tc-TP3982 and (99m)Tc-TP3654.

    In plain wordsIn mice with breast tumors, the copper-labelled VIP analog reached the tumor in higher amounts than the technetium-labelled analogs.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseTumor uptake at 4 h
    Study

    mousen: not reported in source

    Human T47D breast tumor xenografts in athymic nude mice
    Comparator
    (99m)Tc-TP3982 and (99m)Tc-TP3654
    Outcome group
    Diagnostic imaging · Cancer

    Measurements

    Tumor uptake
    10.8 %ID/g
    (64)Cu-TP3982, 4 h
    Tumor uptake
    0.5 %ID/g
    (99m)Tc-TP3982, 4 h
    Tumor uptake
    0.24 %ID/g
    (99m)Tc-TP3654, 4 h

    Source sentences

    Summary
    With (64)Cu-TP3982, the 4-h postinjection tumor uptake was 10.8 +/- 2.1 %ID/g versus 0.5 +/- 0.02 %ID/g and 0.24 +/- 0.08 %ID/g for (99m)Tc-TP3982 and (99m)Tc-TP3654, respectively.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Pharmacokinetics

    In mice with T47D breast tumor xenografts, 24-h tumor uptake was higher for (64)Cu-TP3982 than for (99m)Tc-TP3982 and (99m)Tc-TP3654.

    In plain wordsIn mice with breast tumors, a day after injection the copper-labelled VIP analog still reached the tumor in higher amounts than the technetium-labelled analogs.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseTumor uptake at 24 h
    Study

    mousen: not reported in source

    Human T47D breast tumor xenografts in athymic nude mice
    Comparator
    (99m)Tc-TP3982 and (99m)Tc-TP3654
    Outcome group
    Diagnostic imaging · Cancer

    Measurements

    Tumor uptake
    17 %ID/g
    (64)Cu-TP3982, 24 h
    Tumor uptake
    0.77 %ID/g
    (99m)Tc-TP3982, 24 h
    Tumor uptake
    0.23 %ID/g
    (99m)Tc-TP3654, 24 h

    Source sentences

    Summary
    Twenty-four hours after injection, the corresponding numbers were 17 +/- 0.7 %ID/g, 0.77 +/- 0.1 %ID/g, and 0.23 +/- 0.1 %ID/g.
    1 context sentence
    Summary · context
    With (64)Cu-TP3982, the 4-h postinjection tumor uptake was 10.8 +/- 2.1 %ID/g versus 0.5 +/- 0.02 %ID/g and 0.24 +/- 0.08 %ID/g for (99m)Tc-TP3982 and (99m)Tc-TP3654, respectively.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In mice with T47D breast tumor xenografts, blocking receptors with VIP(28) reduced uptake of (64)Cu-TP3982 in all tissues except the liver at 4 h.

    In plain wordsIn mice with breast tumors, blocking VIP receptors reduced uptake of the labelled VIP analog in all tissues except the liver.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseTissue uptake of (64)Cu-TP3982 after receptor blocking
    Study

    mousen: not reported in source

    Human T47D breast tumor xenografts in athymic nude mice
    Comparator
    No receptor blocking
    Outcome group
    Diagnostic imaging · Cancer

    Source sentences

    Summary
    Four hours after receptor blocking with VIP(28), there was a significant reduction in uptake of all tissues except in the liver.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  6. 06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    The biologic activity of both VIP analogs was uncompromised in smooth muscle relaxivity assays that compared them with unaltered VIP(28).

    In plain wordsIn lab tests, the VIP analogs kept their biologic activity.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeBiologic activity of VIP analogs
    Study

    n: not reported in source

    Smooth muscle relaxivity assays
    Outcome group
    Diagnostic imaging · Cancer

    Source sentences

    Summary
    The biologic activity of both VIP analogs was uncompromised.
    1 context sentence
    Summary · context
    Smooth muscle relaxivity assays performed with each derivative and compared with unaltered VIP(28) demonstrated functional integrity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  7. 07LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Other

    Labeling yields were 98% for (64)Cu-TP3982, 98.2% for (99m)Tc-TP3982 and 97% for (99m)Tc-TP3654.

    In plain wordsIn lab tests, the VIP analog took up its radioactive label with yields of about 97 to 98%.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableRadiolabeling yield of VIP analog
    Study

    n: not reported in source

    Outcome group
    Diagnostic imaging · Cancer

    Measurements

    Labeling yield
    98%
    (64)Cu-TP3982
    Labeling yield
    98.2%
    (99m)Tc-TP3982
    Labeling yield
    97%
    (99m)Tc-TP3654

    Source sentences

    Summary
    (64)Cu-TP3982 labeling yields were 98% +/- 1.2% and those for (99m)Tc-TP3982 and (99m)Tc-TP3654 were 98.2% +/- 1.1% and 97% +/- 1.6%, respectively.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  8. 08LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Pharmacokinetics

    After challenge with 100-mol excess of DTPA, HSA or cysteine, more than 98% of radioactivity remained as (64)Cu-TP3982.

    In plain wordsIn lab tests, the labelled VIP analog stayed intact when challenged with chemicals and proteins.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableIn vitro stability of (64)Cu-TP3982
    Study

    n: not reported in source

    Outcome group
    Diagnostic imaging · Cancer

    Measurements

    Intact radiolabelled analog
    > 98%
    after DTPA, HSA or cysteine challenge

    Source sentences

    Summary
    When (64)Cu-TP3982 was challenged with 100-mol excess of DTPA, HSA, or cysteine, >98% radioactivity remained as (64)Cu-TP3982.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  9. 09LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Other

    SELDI-TOF mass spectrometry gave a mass of 4,049.7 Da for the Cu-TP3982 complex.

    In plain wordsIn lab tests, the mass of the copper-labelled VIP analog was measured as 4,049.7 Da.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableMass of the Cu-TP3982 complex
    Study

    n: not reported in source

    Outcome group
    Diagnostic imaging · Cancer

    Measurements

    Mass
    4049.7 Da
    Cu-TP3982 complex, SELDI-TOF

    Source sentences

    Summary
    The mass of Cu-TP3982 as determined by surface-enhanced laser desorption/ionization time of flight (SELDI-TOF) was 4,049.7 Da.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.